GI Cancer Clinical Roundup
(BMS) Oct 16, 2020 - Application based on Phase 3 ATTRACTION-3 trial demonstrating a statistically significant and clinically meaningful improvement in patients’ overall survival compared to chemotherapy.
(Yahoo! Finance) Oct 12, 2020 - Basilea Pharmaceutica Ltd. today reported that its fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, demonstrated antitumor efficacy in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 gene mutations or amplifications.
(Yahoo! Finance) Sept 30, 2020 - Genetron Holdings Limited today announced that its blood-based next-generation sequencing (NGS) test, HCCscreenTM, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer
At ESMO Virtual Congress 2020, the results from three randomized phase 3 clinical trials — CheckMate 649, ATTRACTION-4, and KEYNOTE-590 — made one thing clear: Immunotherapy benefits patients with gastric and esophageal cancers. As for the adjuvant setting, which had no standard of care, the results from the phase 3 CheckMate 577 trial point to nivolumab as a new option.